BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 10700911)

  • 21. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
    Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
    Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ; Grugni A; Kini MS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
    Gelber RH; Balagon VF; Cellona RV
    Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
    Vijayakumaran P; Jesudasan K; Manimozhi N
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
    Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
    J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study on trend of relapse in leprosy and factors influencing relapse.
    Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
    Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
    Katoch K; Katoch VM; Natarajan M; Gupta UD; Sharma VD; Singh HB
    Indian J Lepr; 2008; 80(4):331-44. PubMed ID: 20329382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of relapse in leprosy. The Leprosy Unit, WHO.
    Indian J Lepr; 1995; 67(1):13-26. PubMed ID: 7622926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Problems of leprosy relapse in China.
    Li HY
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
    Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
    Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An 8-12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multi-drug therapy.
    Desikan KV; Sundaresh P; Tulasidas I; Rao PV
    Lepr Rev; 2008 Sep; 79(3):303-10. PubMed ID: 19009979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment of paucibacillary leprosy under multidrug therapy-three years followup study.
    Revankar CR; Karjivkar VG; Gurav VJ; Ganapati R
    Indian J Lepr; 1989 Jul; 61(3):355-9. PubMed ID: 2768883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P; Manimozhi N; Jesudasan K
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
    Pönnighaus JM; Boerrigter G
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of MDT in multibacillary leprosy.
    Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.